Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Celyad Oncology stock

CYAD.BR
BE0974260896
A1W7Q9

Price

0.73
Today +/-
+0.09
Today %
+12.96 %

Celyad Oncology stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Celyad Oncology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Celyad Oncology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Celyad Oncology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Celyad Oncology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Celyad Oncology Stock Price History

DateCelyad Oncology Price
11/29/20240.73 undefined
11/28/20240.64 undefined
11/27/20240.67 undefined
11/26/20240.65 undefined
11/25/20240.67 undefined
11/22/20240.65 undefined
11/21/20240.65 undefined
11/20/20240.69 undefined
11/19/20240.68 undefined
11/18/20240.67 undefined
11/15/20240.69 undefined
11/14/20240.45 undefined
11/13/20240.50 undefined
11/12/20240.56 undefined
11/11/20240.72 undefined
11/8/20240.67 undefined
11/7/20241.00 undefined
11/6/20240.67 undefined
11/5/20240.37 undefined
11/4/20240.35 undefined
11/1/20240.30 undefined

Celyad Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Celyad Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celyad Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celyad Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Celyad Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Celyad Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Celyad Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celyad Oncology’s growth potential.

Celyad Oncology Revenue, EBIT and net profit per share

DateCelyad Oncology RevenueCelyad Oncology EBITCelyad Oncology Net Income
2025e156.25 M undefined-13.81 M undefined15.41 M undefined
2024e62.5 M undefined-10.67 M undefined20.21 M undefined
2023102,000 undefined-9.54 M undefined-8.45 M undefined
20220 undefined-5.77 M undefined-40.94 M undefined
20210 undefined-26.39 M undefined-26.51 M undefined
20205,000 undefined-16.98 M undefined-17.2 M undefined
20196,000 undefined-28.88 M undefined-28.63 M undefined
20183.12 M undefined-37.99 M undefined-37.43 M undefined
20173.54 M undefined-26.6 M undefined-56.4 M undefined
20168.52 M undefined-25.61 M undefined-23.61 M undefined
20153,000 undefined-29.67 M undefined-29.11 M undefined
2014146,000 undefined-16.44 M undefined-16.45 M undefined
20130 undefined-12.95 M undefined-14.49 M undefined
201250,000 undefined-12.9 M undefined-13.52 M undefined
20110 undefined-9.3 M undefined-9.35 M undefined
20101.52 M undefined-6.42 M undefined-6.71 M undefined

Celyad Oncology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e
1000008330000062156
--------62.50-------151.61
-100.00-----100.00100.00100.00-----4.841.92
-1-3-5-6-1208330000000
-6-9-13-14-16-29-23-56-37-28-17-26-40-82015
-50.0044.447.6914.2981.25-20.69143.48-33.93-24.32-39.2952.9453.85-80.00-350.00-25.00
0.931.211.214.16.758.489.319.6311.1412.5213.9415.622.5925.7200
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Celyad Oncology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Celyad Oncology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20102011201220132014201520162017201820192020202120222023
                           
4.22.41.622.130.3107.5182.5933.9149.7439.3417.2330.0212.457
1.70.20.20.10.030.060.050.060.280.160.170.20.910.38
0.30.80.20.32.391.32.111.681.082.70.742.140.352.4
00000000000000
0.30.20.20.10.330.540.620.740.590.651.561.931.121.34
6.53.62.222.633.06109.4285.3736.3951.6942.8419.7134.2914.8311.12
0.60.40.40.20.61.143.563.293.015.064.123.250.311.83
200200200100018000000000
00000001.163.225.485.85.973.452.8
10.29.69.69.410.2747.7948.5335.5935.2835.3235.2935.290.860.39
0000011.040.910.880.880.880.8800
000001310273214257293262264137
1110.210.29.710.8650.1153.4441.2342.614746.3845.654.895.16
17.513.812.432.343.92159.53138.8177.6394.389.8466.0879.9419.7216.28
                           
001022.124.6232.5732.5734.3441.5548.5148.5178.5978.5932.95
00033.353.3158.01158.01170.3206.1543.3543.356.326.320
8.7-0.3-23.6-38.6-51.23-100.31-124.03-180.42-217.78-74.42-91.83-74.44-115.39-62.38
0411.40021.224.3323.3225.6628.1830.9633.1734.835.73
00000000000000
8.73.7-2.216.826.68111.4790.8847.5455.5945.6230.9943.644.326.3
1.31.11.82.24.048.588.14.85.926.974.746.614.751.24
0.40.50.60.61.071.61.51.251.672.231.972.131.390.5
0.20.310.50.811.071.121.261.31.364.014.184.151.04
00000000000000
0.30.20.20.10.130.250.560.640.771.361.110.90.140.16
2.22.13.63.46.0511.4911.287.959.6511.9211.8313.8310.432.93
0.20.10.100.280.430.920.810.8832.531.730.120.9
00000000000000
6.37.811.212.110.9636.1435.7321.3428.1829.2920.7320.754.866.14
6.57.911.312.111.2436.5636.6522.1529.0632.323.2622.484.977.05
8.71014.915.517.2948.0547.9230.0938.7144.2235.0936.315.49.98
17.413.712.732.343.98159.52138.8177.6394.389.8466.0879.9419.7216.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Celyad Oncology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Celyad Oncology's financial health and stability.

Assets

Celyad Oncology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Celyad Oncology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Celyad Oncology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Celyad Oncology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2010201120122013201420152016201720182019202020212022
-6-9-13-14-16-29-23-56-37-28-17-26-40
000001,0001,0001,0001,0001,0001,0001,0001,000
0000000000000
-3,000-1,0000001,000-1,000-3,00000-2,0001,000-1,000
1143-1001380-10-313
0000000000000
0000000000000
-8-7-8-10-17-27-24-44-27-28-27-26-28
000000-10-10000
000-3-1-10-301708007
000-3-1-9-281829007
0000000000000
136000000-1-1-1-1
30030251090043160360
85831271103043185393
3220212003644
0000000000000
0-2017872-51-2517-1-2212-17
-8.38-7.67-9-11.17-18.05-28.14-26.47-45.3-29.01-28.82-27.98-27.04-28.13
0000000000000

Celyad Oncology stock margins

The Celyad Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celyad Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celyad Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Celyad Oncology's sales revenue. A higher gross margin percentage indicates that the Celyad Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Celyad Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Celyad Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celyad Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celyad Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celyad Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Celyad Oncology Margin History

Celyad Oncology Gross marginCelyad Oncology Profit marginCelyad Oncology EBIT marginCelyad Oncology Profit margin
2025e32.35 %-8.84 %9.86 %
2024e32.35 %-17.08 %32.34 %
202332.35 %-9,356.86 %-8,282.35 %
202232.35 %0 %0 %
202132.35 %0 %0 %
2020100 %-339,540 %-344,080.03 %
2019100 %-481,316.65 %-477,200 %
2018100 %-1,219.52 %-1,201.51 %
201785.45 %-751.5 %-1,593.08 %
201699.38 %-300.47 %-276.97 %
201566.67 %-989,066.7 %-970,466.7 %
2014-8,407.53 %-11,258.22 %-11,269.18 %
201332.35 %0 %0 %
2012-11,320 %-25,800 %-27,040 %
201132.35 %0 %0 %
2010-109.87 %-422.37 %-441.45 %

Celyad Oncology Stock Sales Revenue, EBIT, Earnings per Share

The Celyad Oncology earnings per share therefore indicates how much revenue Celyad Oncology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Celyad Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Celyad Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Celyad Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Celyad Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Celyad Oncology Revenue, EBIT and net profit per share

DateCelyad Oncology Sales per ShareCelyad Oncology EBIT per shareCelyad Oncology Earnings per Share
2025e3.77 undefined0 undefined0.37 undefined
2024e1.51 undefined0 undefined0.49 undefined
20230 undefined-0.37 undefined-0.33 undefined
20220 undefined-0.26 undefined-1.81 undefined
20210 undefined-1.69 undefined-1.7 undefined
20200 undefined-1.22 undefined-1.23 undefined
20190 undefined-2.31 undefined-2.29 undefined
20180.28 undefined-3.41 undefined-3.36 undefined
20170.37 undefined-2.76 undefined-5.86 undefined
20160.92 undefined-2.75 undefined-2.53 undefined
20150 undefined-3.5 undefined-3.43 undefined
20140.02 undefined-2.43 undefined-2.44 undefined
20130 undefined-3.16 undefined-3.53 undefined
20120.04 undefined-10.66 undefined-11.17 undefined
20110 undefined-7.69 undefined-7.73 undefined
20101.63 undefined-6.9 undefined-7.22 undefined

Celyad Oncology business model

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology is one of the most popular companies on Eulerpool.com.

Celyad Oncology SWOT Analysis

Strengths

Celyad Oncology possesses several strengths that contribute to its competitive advantage in the oncology sector. These strengths include:

  • Advanced Technology: Celyad Oncology employs cutting-edge technology in the development of its innovative cell-based immunotherapy solutions.
  • Strong Research and Development: The company has a robust R&D pipeline, with a focus on developing novel therapies for a wide range of cancers.
  • Strategic Partnerships: Celyad Oncology has established collaborations with leading academic institutions and industry partners, enhancing its research capabilities and market reach.
  • Experienced Management Team: The company is led by a team of experts with extensive experience in the biotechnology and oncology sectors, ensuring effective decision-making and execution of strategies.

Weaknesses

Despite its strengths, Celyad Oncology also faces certain weaknesses that may hinder its growth and market position. These weaknesses include:

  • Limited Commercialization: The company's products are still in the early stages of development, resulting in limited commercialization and revenue generation.
  • Dependency on Partnerships: While partnerships provide advantages, Celyad Oncology's reliance on collaborations may potentially limit its control over the development, pricing, and distribution of its therapies.
  • Regulatory Risks: The biotechnology industry is subject to stringent regulations, and any delays or failures in obtaining regulatory approvals can significantly impact the company's timelines and financial performance.

Opportunities

Celyad Oncology can capitalize on various opportunities within the oncology market to drive its growth and success. These opportunities include:

  • Increasing Demand for Innovative Therapies: With the rising prevalence of cancer and the demand for more effective treatments, Celyad Oncology can seize the opportunity to address unmet medical needs with its innovative cell-based immunotherapies.
  • Global Expansion: The company can explore expansion opportunities into new geographic regions to target larger patient populations and expand its market presence.
  • Strategic Collaborations: Forming partnerships with pharmaceutical companies or biotech firms can accelerate the development and commercialization of Celyad Oncology's therapies, enhancing its competitiveness.

Threats

Celyad Oncology also faces several threats that may pose challenges to its growth and sustainability. These threats include:

  • Intense Competition: The oncology sector is highly competitive, with numerous established biopharmaceutical companies and startups vying for market share, making it crucial for Celyad Oncology to differentiate itself and outperform competitors.
  • Industry Challenges: The biotechnology industry is characterized by high development costs, long regulatory timelines, and complex manufacturing processes. These factors can pose significant challenges to Celyad Oncology's operations and financial performance.
  • Emerging Technologies: Rapid advancements in technologies and therapies may render Celyad Oncology's current offerings less competitive, emphasizing the need for continuous innovation and adaptation to remain relevant.

Celyad Oncology Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Celyad Oncology Revenue by Segment

Segmente2022
Immuno oncology [member]-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Celyad Oncology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Celyad Oncology historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Celyad Oncology shares outstanding

The number of shares was Celyad Oncology in 2023 — This indicates how many shares 25.722 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Celyad Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Celyad Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Celyad Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Celyad Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Celyad Oncology.

Celyad Oncology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2017-1.54 -4.3  (-179.18 %)2017 Q4
6/30/2016-1.92 -1.82  (5.09 %)2016 Q2
12/31/2015-1.81 -1.33  (26.33 %)2015 Q4
6/30/2015-1.91 -2.1  (-10.1 %)2015 Q2
1

Celyad Oncology shareholders

%
Name
Stocks
Change
Date
55.17602 % Fortress Investment Group, L.L.C.22,858,6548,222,3104/5/2024
10.16004 % TOLEFI SA4,209,1631,514,2514/5/2024
0.37788 % Lussier (Michel E J)156,55011,4004/5/2024
0.17534 % BNP Paribas Asset Management Belgium S.A.72,64108/31/2024
0.13561 % Goblet (Serge)56,18004/5/2024
0 % Inversis Gesti¿n, S.A., SGIIC0-5,82612/31/2023
1

Celyad Oncology Executives and Management Board

Mr. Michel Lussier

(58)
Celyad Oncology Interim Chief Executive Officer, Director (since 2007)
Compensation 97,970

Mr. Dominic Piscitelli

(49)
Celyad Oncology Independent Director
Compensation 65,000

Mr. Chris Buyse

(56)
Celyad Oncology Non-Executive Director (since 2020)
Compensation 63,470

Ms. Hilde Windels

(58)
Celyad Oncology Chairwoman of the Board (since 2018)
Compensation 63,000

Mr. Serge Goblet

Celyad Oncology Non-Executive Director
Compensation 43,480
1
2
3

Celyad Oncology Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck & Co Stock
Merck & Co
SupplierCustomer0,59-0,55-0,51-0,71-0,60-0,39
Mesoblast Stock
Mesoblast
SupplierCustomer-0,650,370,700,800,810,87
Novartis Stock
Novartis
SupplierCustomer-0,680,27-0,65-0,62-0,16-0,11
1

Most common questions regarding Celyad Oncology

What values and corporate philosophy does Celyad Oncology represent?

Celyad Oncology represents a commitment to innovative cell-based therapies for cancer treatment. The company's corporate philosophy revolves around leveraging its expertise in cell engineering and immune-oncology to develop groundbreaking therapies. Celyad Oncology aims to improve patient outcomes and quality of life by delivering personalized and targeted treatments. With a strong focus on research and development, Celyad Oncology strives to stay at the forefront of medical advancements, collaborating with scientific and clinical partners to advance the field of cellular immunotherapy. The company's dedication to scientific rigor and a patient-centric approach drives its pursuit of transformative solutions in the fight against cancer.

In which countries and regions is Celyad Oncology primarily present?

Celyad Oncology is primarily present in multiple countries and regions around the globe. With a strong global presence, the company operates in key markets such as Europe, the United States, and Asia. Celyad Oncology's commitment to advancing cell-based therapies extends to various regions, allowing it to reach a wide patient population in pursuit of innovative treatments for various oncology indications.

What significant milestones has the company Celyad Oncology achieved?

Celyad Oncology, a leading biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the successful completion of the Phase 1 THINK trial for CYAD-01, their proprietary NKG2D-based CAR-T therapy. Another achievement includes the initiation of the Phase 1 alloSHRINK trial, evaluating CYAD-101, their first-in-class non-gene edited allogeneic CAR-T candidate. Furthermore, Celyad Oncology has entered into a strategic collaboration with ONO Pharmaceutical Co., Ltd., aiming to develop innovative CAR-T therapies for solid tumors. Additionally, the company has received numerous patents, reinforcing their position as a pioneer in the field of cellular immunotherapy. Celyad Oncology continues to make significant strides in advancing groundbreaking therapies to address unmet medical needs.

What is the history and background of the company Celyad Oncology?

Celyad Oncology, a leading biopharmaceutical company, has an intriguing history and background. Founded in 2004, the company is dedicated to developing innovative CAR-T cell-based therapies for the treatment of cancer. Initially known as Cardio3 BioSciences, Celyad Oncology rebranded itself in 2015, putting a greater focus on oncology research. With a strong emphasis on cellular therapy, particularly utilizing its proprietary CAR-T technology, Celyad Oncology aims to revolutionize cancer treatment by engineering T cells to target and destroy cancer cells effectively. Through clinical trials and strategic collaborations, the company strives to provide potential breakthrough solutions for patients battling various forms of cancer worldwide. Celyad Oncology's relentless commitment and expertise drive its pursuit of improved patient outcomes.

Who are the main competitors of Celyad Oncology in the market?

The main competitors of Celyad Oncology in the market are bluebird bio, Inc., Fate Therapeutics, Inc., and Cellectis S.A. These companies also operate in the field of cell therapy and are known for their innovative approaches in developing advanced treatments for various diseases. However, Celyad Oncology distinguishes itself with its unique proprietary technologies, such as its allogeneic CAR-T platform and its differentiated shRNA platform. With its strong focus on product development and strategic collaborations, Celyad Oncology continues to position itself as a key player in the competitive landscape of the cell therapy market.

In which industries is Celyad Oncology primarily active?

Celyad Oncology is primarily active in the biotechnology and healthcare industries.

What is the business model of Celyad Oncology?

Celyad Oncology is a biopharmaceutical company specializing in the development of innovative cancer treatments. The company's business model focuses on utilizing its proprietary CAR-T cell platform to engineer T-cells to target and destroy cancer cells. Through extensive research and clinical trials, Celyad aims to address unmet medical needs and improve patient outcomes by developing personalized immunotherapies. By leveraging its expertise in cell therapy and strategic partnerships, Celyad Oncology strives to revolutionize cancer treatment and provide hope for patients worldwide.

What is the P/E ratio of Celyad Oncology 2024?

The Celyad Oncology P/E ratio is 0.93.

What is the P/S ratio of Celyad Oncology 2024?

The Celyad Oncology P/S ratio is 0.3.

What is the Quality Investing of Celyad Oncology?

The Quality Investing for Celyad Oncology is 3/10.

What is the revenue of Celyad Oncology 2024?

The expected Celyad Oncology revenue is 62.5 M EUR.

How high is the profit of Celyad Oncology 2024?

The expected Celyad Oncology profit is 20.21 M EUR.

What is the business model of Celyad Oncology

Celyad Oncology is an innovative biotechnology company focused on the development of cancer therapies. Its business model is centered around researching new treatment options to fight cancer. Celyad Oncology has various divisions that engage in research, development, production, and marketing of therapeutic products. One of its key divisions is CAR-T technology, which involves modifying a patient's T-cells to specifically recognize and kill cancer cells. The company is dedicated to optimizing the potential of this therapy through innovative technologies. Additionally, Celyad Oncology is involved in researching and developing other cancer treatment options such as allogeneic stem cell transplantation and the use of TCR-T cells. The company collaborates with leading research institutions and other companies to drive innovation in cancer treatment. Celyad Oncology is also involved in the production and marketing of therapeutic products, including CYAD-01, a treatment for metastatic colorectal and esophageal cancer. The company continuously strives to expand and enhance its portfolio of therapies in order to provide better healthcare to patients worldwide. Its business model relies on collaboration with other companies and institutions to advance cancer treatment. One of its key partnerships is with Novartis, a leading healthcare company, to jointly develop and market cancer therapies for the benefit of cancer patients. In summary, Celyad Oncology's business model is focused on the research, development, production, and marketing of cancer therapies. The company has various divisions dedicated to the exploration and development of new treatment options, and it already offers innovative products for cancer treatment. Celyad Oncology works closely with other companies and institutions to advance cancer treatment and provide better healthcare to patients worldwide.

What is the Celyad Oncology dividend?

Celyad Oncology pays a dividend of 0 EUR distributed over payouts per year.

How often does Celyad Oncology pay dividends?

The dividend cannot currently be calculated for Celyad Oncology or the company does not pay out a dividend.

What is the Celyad Oncology ISIN?

The ISIN of Celyad Oncology is BE0974260896.

What is the Celyad Oncology WKN?

The WKN of Celyad Oncology is A1W7Q9.

What is the Celyad Oncology ticker?

The ticker of Celyad Oncology is CYAD.BR.

How much dividend does Celyad Oncology pay?

Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.

What is the dividend yield of Celyad Oncology?

The current dividend yield of Celyad Oncology is .

When does Celyad Oncology pay dividends?

Celyad Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celyad Oncology?

Celyad Oncology paid dividends every year for the past 0 years.

What is the dividend of Celyad Oncology?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celyad Oncology located?

Celyad Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celyad Oncology from 11/30/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/30/2024.

When did Celyad Oncology pay the last dividend?

The last dividend was paid out on 11/30/2024.

What was the dividend of Celyad Oncology in the year 2023?

In the year 2023, Celyad Oncology distributed 0 EUR as dividends.

In which currency does Celyad Oncology pay out the dividend?

The dividends of Celyad Oncology are distributed in EUR.

All fundamentals about Celyad Oncology

Our stock analysis for Celyad Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celyad Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.